Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13376707 | 0.82 | PRMT3 (0.45) | HTR2COPRL1KCNH2DRD4DRD2 | |
| SCHEMBL10212349 | 0.79 | KDM4E (0.54) | HTR2COPRL1KCNH2HSD11B1KDM4E | |
| SCHEMBL15830146 | 0.79 | KDM4E (0.54) | HTR2COPRL1KCNH2HSD11B1KDM4E | |
| SCHEMBL3436380 | 0.79 | DRD4 (0.52) | HTR2COPRL1KCNH2DRD4HSD11B1 | |
| SCHEMBL23050177 | 0.78 | DRD3 (0.53) | HTR2COPRL1 | |
| SCHEMBL11825969 | 0.77 | OPRL1 (0.51) | HTR2COPRL1KCNH2DRD4DRD2 | |
| SCHEMBL13652034 | 0.77 | HTR2C (0.41) | HTR2COPRL1KCNH2DRD4KMT2A | |
| SCHEMBL13450177 | 0.77 | MEN1 (0.67) | OPRL1DRD4KMT2ADRD2ACHE | |
| SCHEMBL3436371 | 0.77 | SLC18A3 (0.61) | HTR2COPRL1KCNH2DRD4DRD2 | |
| SCHEMBL9912160 | 0.77 | DRD2 (0.66) | DRD4KMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | HTR2C 1146/4885OPRL1 51/4885KCNH2 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.